G. S. Walker

发表

Use of microprocessors to control a photographic plate measuring machine

A. C. Daly, G. S. Walker, 1983 .

A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.

G. S. Walker, A. Kalgutkar, A. Mutlib, 2007, Chemical research in toxicology.

Long‐range two‐dimensional 1H–15N heteronuclear shift correlation at natural abundance using GHNMQC. A study of the reverse transcriptase inhibitor delavirdine

G. S. Walker, K. Farley, Gary E Martin, 1997 .

An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota

G. S. Walker, R. Obach, E. van de Steeg, 2018, Drug Metabolism and Disposition.

Spectroscopic studies of delavirdine mesylate (U-90,152T) a bis(heteroaryl)piperazine (BHAP) HIV reverse transcriptase inhibitor

G. S. Walker, R. H. Robins, J. Gage, 1996 .

Non-Classical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open Source Antimalarials.

G. S. Walker, Mark B. Anderson, R. Obach, 2020, Journal of medicinal chemistry.

Enzalutamide and Apalutamide: In vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.

G. S. Walker, R. Obach, M. Guha, 2020, Chemical research in toxicology.

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

G. S. Walker, A. Kalgutkar, R. Obach, 2022, Drug Metabolism and Disposition.

Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

G. S. Walker, L. Wienkers, J. M. Hutzler, 2003, Chemical research in toxicology.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs

G. S. Walker, R. Obach, R. Walsky, 2012, Drug Metabolism and Disposition.

In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam.

R Scott Obach, G. S. Walker, A. Kalgutkar, 2008, Chemical research in toxicology.

Late Stage Lead Diversification (LSLD) Coupled with Quantitative NMR Spectroscopy to Identify New SAR Vectors at Nanomole Scale Synthesis: Application to Loratadine a Human Histamine H1 Receptor Inverse Agonist.

G. S. Walker, R. Obach, N. Sach, 2020, Journal of medicinal chemistry.

Boston Society's 11th Annual Applied Pharmaceutical Analysis conference.

G. S. Walker, James R. Schiller, E. Groeber, 2016, Bioanalysis.

Characterization of T-5 N-Oxide Formation as the First Highly Selective Measure of CYP3A5 Activity

G. S. Walker, S. Heyward, M. Cameron, 2014, Drug Metabolism and Disposition.

Characterization of T-5 N -Oxide Formation as the First Highly Selective Measure of CYP3A5 Activity

G. S. Walker, S. Heyward, M. Cameron, 2014 .

Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides

A. D. Rodrigues, G. S. Walker, L. Tremaine, 2017, Drug Metabolism and Disposition.

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

G. S. Walker, T. R. Johnson, J. Christensen, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

In Vitro Kinetic Characterization of Axitinib Metabolism

G. S. Walker, J. Bauman, T. Goosen, 2016, Drug Metabolism and Disposition.

DMD065615 102..114

G. S. Walker, J. Bauman, T. Goosen, 2015 .

2 Running Title : In vitro metabolism of axitinib

G. S. Walker, J. Bauman, T. Goosen, 2015 .

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

G. S. Walker, C. Prakash, G. Chan, 2014, Drug Metabolism and Disposition.

DMD054940 759..773

G. S. Walker, C. Prakash, G. Chan, 2014 .

THE EFFECTIVE APPLICATION OF METABOLITE PROFILING IN DRUG DESIGN AND DISCOVERY.

G. S. Walker, A. Kalgutkar, R. Obach, 2020, Journal of medicinal chemistry.

Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR

G. S. Walker, A. Freund, Gregory S. Walker, 2011, Drug Metabolism and Disposition.

Identification of Drug Metabolites

G. S. Walker, D. Dalvie, Gregory S. Walker, 2012 .

Comparison of In Vitro Metabolism of Ticlopidine by Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4

G. S. Walker, J. Halpert, D. Dalvie, 2011, Drug Metabolism and Disposition.

Metabolic Aromatization of N-Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish Peroxidase

G. S. Walker, R. Voorman, D. Holsworth, 2006, Drug Metabolism and Disposition.

Acyl Glucuronide Metabolites of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 H-indole-3-carboxylic Acid (PF-06409577) and Related Indole-3-carboxylic Acid Derivatives are Direct Activators of Adenosine Monophosphate-Activated Protein Kinase (AMPK).

G. S. Walker, R. Kurumbail, Jake E. Delmore, 2018, Journal of medicinal chemistry.

Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.

G. S. Walker, V. Shanmugasundaram, R. Obach, 2014, Journal of medicinal chemistry.

Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy.

G. S. Walker, J. Bauman, M. Reily, 2007, Chemical research in toxicology.

Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5

G. S. Walker, R. Obach, T. Goosen, 2018, Drug Metabolism and Disposition.

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

G. S. Walker, J. Bauman, J. Telliez, 2022, Drug Metabolism and Disposition.

Identifying a Selective Substrate and Inhibitor Pair for the Evaluation of CYP2J2 Activity

G. S. Walker, Caroline A. Lee, J. Jones, 2012, Drug Metabolism and Disposition.

Increased HMBC Sensitivity for Correlating Poorly Resolved Proton Multiplets to Carbon-13 Using Selective or Semi-selective Pulses

G. S. Walker, A. Bax, K. Farley, 1996 .

Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development

G. S. Walker, A. Kalgutkar, A. Bergman, 2022, Clinical pharmacology and therapeutics.

Comparison of LC-NMR and conventional NMR for structure elucidation in drug metabolism studies

G. S. Walker, T. O’Connell, Gregory S. Walker, 2008 .

Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma.

G. S. Walker, A. Stepan, A. Kalgutkar, 2011, Chemical research in toxicology.

The use of 18O-exchange and base-catalyzed N-dealkylation with liquid chromatography/tandem mass spectrometry to identify carbinolamide metabolites.

G. S. Walker, A. Vaz, Gregory S. Walker, 2010, Rapid communications in mass spectrometry : RCM.

Non-Uniform Sampling for All: More NMR Spectral Quality, Less Measurement Time.

Robert G. Brinson, Luke W. Arbogast, G. S. Walker, 2017, American pharmaceutical review.

Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-Based Inverse Agonists of the Ghrelin Receptor

G. S. Walker, A. Kalgutkar, T. Goosen, 2013, Drug Metabolism and Disposition.

Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189

G. S. Walker, A. Stepan, R. Obach, 2018, ACS Medicinal Chemistry Letters.

Harnessing biosynthesis and quantitative NMR for late stage functionalization of lead molecules: Application to the M1 positive allosteric modulator (PAM) program.

G. S. Walker, R. Scott Obach, M. Brodney, 2018, Bioorganic & medicinal chemistry letters.

Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.

G. S. Walker, V. Shanmugasundaram, M. Hayward, 2014, Journal of medicinal chemistry.

Biosynthesis of Drug Metabolites and Quantitation Using NMR Spectroscopy for Use in Pharmacologic and Drug Metabolism Studies

G. S. Walker, J. Bauman, R. Obach, 2014, Drug Metabolism and Disposition.

DMD059204 1627..1639

G. S. Walker, J. Bauman, R. Obach, 2014 .

Characterization of T-5 N-Oxide Formation as the First Highly Selective Measure of CYP3A5 Activity

G. S. Walker, S. Heyward, M. Cameron, 2014, Drug Metabolism and Disposition.

Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in human.

G. S. Walker, R. Obach, J. W. Wong, 2013, Journal of pharmaceutical sciences.

Metabolism of a dopamine receptor partial agonist in rats, including an unusual N-dearylation reaction.

G. S. Walker, R. Obach, Gregory S. Walker, 2011, Drug metabolism and pharmacokinetics.

Insights into the novel hydrolytic mechanism of a diethyl 2-phenyl-2-(2-arylacetoxy)methyl malonate ester-based microsomal triglyceride transfer protein (MTP) inhibitor.

G. S. Walker, A. Kalgutkar, D. Hepworth, 2012, Chemical research in toxicology.